Structure Encountered
Ternary Therapeutics
AI-driven platform developing molecular glue therapeutics for undruggable targets in immunology
Ternary Therapeutics is betting AI can turn biotech's luckiest modality into an engineered one.
SIGNAL·FUNDING RADAR·SCORE 82·02 APR 2026 · 22:33 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / TERNARY THERAPEUTICS
CAPT. / 02.04.26 22:33:00Z
SIGNAL / 82 / 100
Image relayed by The Biotech Voyager during pass over structure Ternary Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Ternary Therapeutics
Stage
Preclinical
Type
Therapeutics
Modalities
small molecule · AI/ML
Therapeutic area
Immunology · Fibrosis · Neurology
002Signature Detected
FUNDING EVENT
Event type
Seed — Closed
Magnitude
$0M
Lead investor
daphni
Participating
Pace Ventures, i&i Biotech Fund, UK Innovation & Science Seed Fund (UKI2S)
Round date
16 Mar 2026
003Architecture
AWAITING ENRICHMENT
Target class · differentiator · lead asset · pipeline depth populate once the writer fills these fields on this row.
004Voyager Assessment
STRUCTURE PROFILE
Ternary Therapeutics (TernaryTx) is a UK-based biotechnology company that develops an AI-driven platform for designing molecular glue therapeutics. The company uses computational methods including AI-powered target assessment, geometric deep learning, and molecular dynamics simulations to rationally design molecular glues that can degrade or modulate previously undruggable protein targets. Founded by Dr. Chris Tame, a veteran in AI-driven drug discovery with experience at BenevolentAI and GSK, the team focuses primarily on immunology therapeutic areas including inflammatory and fibrotic diseases, as well as neuroinflammation. The platform enables systematic discovery of molecular glues for targets that lack traditional starting points, addressing diseases with high unmet medical needs beyond oncology. The company operates labs at the Stevenage Bioscience Catalyst with headquarters in London. Programs are currently in preclinical development stages. The company is currently active as a private company, incorporated in October 2024.
005Tags
HOUSTON CLASSIFIED
Funding RadarAImolecular glueprotein degradationdrug discovery
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.